Dako, Bristol-Myers Ink Pharmacogenomics Deal | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dako today said that it has signed an agreement with Bristol-Myers Squibb to develop pharmacogenomics tests to identify patients that are more likely to respond to drugs being developed by the drug firm.

The deal builds on a similar agreement between the firms reached in 2008. Terms of the newest agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.